Primary large B-cell lymphomas of immune-privileged sites
Edited by Associate Editor Michael Hallek and Podcast Editor Laurie H. Sehn, this Review Series highlights the biologic features of, clinical phenotype of,
Edited by Associate Editor Michael Hallek and Podcast Editor Laurie H. Sehn, this Review Series highlights the biologic features of, clinical phenotype of,
In a Peer Exchange, HCC experts discussed how new data from the HIMALAYA, LEAP-012, EMERALD-1, and IMbrave050 trials could be used to optimize treatment.
New cell therapy shows potential in treating advanced blood disorder
Matthew Hadfield, DO, discusses findings from a phase 2 study that used tocilizumab to reduce toxicities with immune checkpoint inhibitors in melanoma.
R. Lor Randall, MD, FACS, discusses the construction and preclinical utility of spheroid models for drug development in osteosarcoma.
Nature Cancer – Sears and colleagues found that ongoing replication stress pathways and T cell clonal responses differentiate liver and lung recurrence and are associated…
Abstract. Gastric cancer (GC) is a major cause of global cancer mortality with high levels of heterogeneity. To explore geospatial interactions in tumor ecosystems, we…
Jonathan Wesley Riess, MD, MS, details the potential for ivonescimab in NSCLC after improving PFS vs pembrolizumab in the HARMONi-2 trial.
Colorectal cancer is the second leading cause of cancer-related death in the United States. Accurate and early detection of CRC and precancerous lesions is critical…
The following infographics are based on New Developments in CAR T Treatments Webinar Series, which aired on Tuesday, September 10, at 12 p.m. CDT and featured…
On Saturday, Dec. 21, Congress passed a new spending package, narrowly averting a government shutdown. To access this subscriber-only content please log in or subscribe.If your…